Share on StockTwits

Thoratec (NASDAQ:THOR) will announce its Q214 earnings results on Wednesday, August 6th. Analysts expect the company to announce earnings of $0.43 per share and revenue of $128.30 million for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

Shares of Thoratec (NASDAQ:THOR) opened at 32.83 on Tuesday. Thoratec has a 52-week low of $30.01 and a 52-week high of $43.58. The stock has a 50-day moving average of $33.50 and a 200-day moving average of $34.13. The company has a market cap of $1.865 billion and a price-to-earnings ratio of 25.39.

A number of research firms have recently commented on THOR. Analysts at Wells Fargo & Co. downgraded shares of Thoratec from an “outperform” rating to a “market perform” rating in a research note on Tuesday, July 29th. On the ratings front, analysts at Raymond James cut their price target on shares of Thoratec from $44.00 to $41.00 in a research note on Monday, July 14th. Finally, analysts at TheStreet upgraded shares of Thoratec from a “hold” rating to a “buy” rating in a research note on Tuesday, July 8th. Four research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $42.00.

Thoratec Corporation is engaged in mechanical circulatory support with a product portfolio to treat the range of clinical needs for advanced heart failure (NASDAQ:THOR) patients.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.